Pharmosa Biopharm Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '24 Sep 9, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	8,180	10,314	7,055	-	-
Market Cap Growth	-29.92%	46.19%	-	-	-
Enterprise Value	6,556	9,330	6,778	-	-
Last Close Price	63.40	88.00	62.22	-	-
PE Ratio	276.61	1257.14	-23.00	-	-
PS Ratio	23.40	32.79	-	-	-
PB Ratio	4.11	9.07	9.27	-	-
P/FCF Ratio	-98.16	-264.20	-26.28	-	-
P/OCF Ratio	161.68	243.13	-27.31	-	-
EV/Sales Ratio	20.23	29.67	-	-	-
EV/EBITDA Ratio	299.91	3121.44	-25.46	-	-
EV/EBIT Ratio	-755.55	-3303.82	-24.96	-	-
EV/FCF Ratio	-70.16	-238.99	-25.25	-	-
Debt / Equity Ratio	0.06	0.13	0.03	0.07	0.31
Debt / EBITDA Ratio	7.46	7.04	-	-	-
Debt / FCF Ratio	-1.35	-3.70	-0.08	-0.15	-0.66
Asset Turnover	0.22	0.29	-	-	-
Quick Ratio	15.76	12.58	24.23	13.96	4.18
Current Ratio	16.29	13.02	24.65	14.39	4.31
Return on Equity (ROE)	2.11%	0.89%	-41.24%	-54.73%	-
Return on Assets (ROA)	-0.42%	-0.17%	-24.49%	-28.67%	-
Return on Capital (ROIC)	-0.43%	-0.17%	-25.13%	-29.48%	-
Earnings Yield	0.36%	0.08%	-3.78%	-	-
FCF Yield	-1.14%	-0.38%	-3.81%	-	-
Buyback Yield / Dilution	-14.02%	-15.09%	-16.02%	-78.34%	-
Total Shareholder Return	-14.02%	-15.09%	-16.02%	-78.34%	-

Source: S&P Capital IQ. Standard template. Financial Sources.